Previous studies suggest that combination of anti-EGFR and anti-IL8 inhibitors markedly enhanced the anti-metastatic effect of breast cancer cells as compared to anti-EGFR alone [58], thus suggesting that combining anti-IL8 and anti-EGFR inhibitors could be an effective treatment for metastatic breast carcinoma. The gene discussed is EGFR; the disease is breast carcinoma.